Latest News
The Chart of the Day belongs to the gastrointestinal pharmaceutical products company Ironwood Pharmaceutical (IRWD) I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the...
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase.
Why Shares of VectivBio Holding Are Up Today
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Weekยฎ 2023
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week ยฎ (DDW) meeting from a Phase III clinical trial on the potential of linaclotide for children and...
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2023 results and recent business performance.
Ironwood to Present New Data at Digestive Disease Weekยฎ 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings during the 2023 Digestive Disease Weekยฎ (DDW) from studies on the potential of linaclotide for children and...
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 4, 2023. Individuals interested in participating in the call...
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences:
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2022 results and recent business performance.
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESSยฎ (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS ยฎ ...
3 No-Brainer Stocks to Buy Right Now for Less Than $25
All three healthcare stocks are showing solid long-term potential.
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in...
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2022 and announced financial guidance for full year 2023. The results were announced in advance of the...
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:00 a.m. Pacific Time /...
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. ET at the Lotte New York Palace.
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2022 results and recent business performance.
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022. Individuals interested in participating in the...
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESSยฎ (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced positive topline data from a Phase III clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC). The trial met its...
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor in Everett, MA.
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESSยฎ Prescription Demand
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2022 results and recent business performance.
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 4, 2022. Individuals interested in participating in the...
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Weekยฎ (DDW) 2022
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week ยฎ (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral...
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Weekยฎ 2022
Ironwood Pharmaceuticals, Inc . (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week ยฎ (DDW) 2022...
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2022 results and recent business performance.